A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: The relevance of the placebo effect and psychological symptoms


Autoria(s): FRAGUAS, Renerio; TELLES, Renata Martinho da Silva; ALVES, Tania Correa Toledo Ferraz; ANDREI, Anna Maria; RAYS, Jairo; IOSIFESCU, Dan V.; WAJNGARTEN, Mauricio
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background: Little is known about the treatment of depression in older patients with heart failure. This Study was developed to investigate the effectiveness of antidepressant treatment for major depressive disorder (MDD) in the elderly with heart failure. Methods: We enrolled 72 older outpatients with ejection fraction < 50 and diagnosed with MDD by the structured clinical interview for DSM-IV. Thirty-seven patients, 19 on citalopram and 18 on placebo, initiated an 8-week double-blind treatment phase. Measurements were performed with the 31-item Hamilton Rating Scale for Depression (Ham-D-31), the Montgomery-Asberg rating scale (MADRS) and the Systematic Assessment for Treatment Emergent Effects (SAFTEE). A psychiatrist followed up the patients weekly, performing a consultation for about 20 min to field complaints after the measurements. Results: A trend toward superiority of citalopram over placebo in reducing depression was observed in MADRS scores (15.05 + 9.74 vs 9.44 + 9.25, P = .082) but not on HAM-D scores. The depressive symptomatology significantly decreased in both groups (P < .001). The high rate of placebo response during the double-blind phase (56.3%) led us to conclude the study at the interim analysis with 37 patients. Conclusion: Citalopram treatment of MDD in older patients with heart failure is well-tolerated with low rates of side effects, but was not significantly more effective than placebo in the treatment of depression. Weekly psychiatric follow-up including counseling may contribute to the improvement of depression in this population. Scales weighted on psychological symptoms such as the MADRS are possibly better suited to measure depression severity and improvement in patients with heart failure. (C) 2009 Elsevier Inc. All rights reserved.

State of Sao Paulo Research Foundation (FAPESP), Brazil[1999/04993-5]

Identificador

CONTEMPORARY CLINICAL TRIALS, v.30, n.3, p.205-211, 2009

1551-7144

http://producao.usp.br/handle/BDPI/23311

10.1016/j.cct.2009.01.007

http://dx.doi.org/10.1016/j.cct.2009.01.007

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

Relação

Contemporary Clinical Trials

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #Heart failure #Depression #Elderly #Double-blind #Randomized controlled trial #Placebo effect #QUALITY-OF-LIFE #SEROTONIN REUPTAKE INHIBITORS #MYOCARDIAL-INFARCTION #CARDIOVASCULAR-DISEASE #ELDERLY-PATIENTS #MILD DEPRESSION #PRIMARY-CARE #PAROXETINE #NORTRIPTYLINE #MORTALITY #Medicine, Research & Experimental #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion